Scientists have developed a drug that targets both major aggregation-promoting sites of the Tau protein, a key player in Alzheimer's disease. This peptide inhibitor, RI-AG03, effectively prevents Tau buildup in lab studies and fruit flies, offering hope for new Alzheimer's treatments.
Scientists have developed a drug that targets both major aggregation-promoting sites of the Tau protein, a key player in Alzheimer's disease. This peptide inhibitor, RI-AG03, effectively prevents Tau buildup in lab studies and fruit flies, offering hope for new Alzheimer's treatments.
Share this Article
Recommended